CARBELIN (Nova Pharmaceuticals Australasia Pty Ltd)
Product name
CARBELIN
Date registered
Evaluation commenced
Decision date
Approval time
118 (255 working days)
Active ingredients
Cabergoline
Registration type
New generic medicine
Indication
Inhibition of physiological lactation
CARBELIN is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons.
Treatment of hyperprolactinemic disorders
CARBELIN is indicated for the treatment of pathological hyperprolactinaemia.